DE60217532T8 - Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas - Google Patents

Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas Download PDF

Info

Publication number
DE60217532T8
DE60217532T8 DE60217532T DE60217532T DE60217532T8 DE 60217532 T8 DE60217532 T8 DE 60217532T8 DE 60217532 T DE60217532 T DE 60217532T DE 60217532 T DE60217532 T DE 60217532T DE 60217532 T8 DE60217532 T8 DE 60217532T8
Authority
DE
Germany
Prior art keywords
ultiplen
myelomas
treatment
carboline derivatives
ikb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE60217532T
Other languages
English (en)
Other versions
DE60217532T2 (de
DE60217532D1 (de
Inventor
Julian Brooklin ADAMS
Kenneth C Wellesley ANDERSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60217532D1 publication Critical patent/DE60217532D1/de
Publication of DE60217532T2 publication Critical patent/DE60217532T2/de
Publication of DE60217532T8 publication Critical patent/DE60217532T8/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60217532T 2001-11-07 2002-11-06 Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas Active DE60217532T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34491101P 2001-11-07 2001-11-07
US344911P 2001-11-07
PCT/US2002/035645 WO2003039545A2 (en) 2001-11-07 2002-11-06 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers

Publications (3)

Publication Number Publication Date
DE60217532D1 DE60217532D1 (de) 2007-02-22
DE60217532T2 DE60217532T2 (de) 2007-10-31
DE60217532T8 true DE60217532T8 (de) 2008-02-07

Family

ID=23352621

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217532T Active DE60217532T8 (de) 2001-11-07 2002-11-06 Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas

Country Status (7)

Country Link
US (1) US9248124B2 (de)
EP (1) EP1443927B1 (de)
JP (2) JP4599501B2 (de)
AU (1) AU2002352498A1 (de)
DE (1) DE60217532T8 (de)
HK (1) HK1069311A1 (de)
WO (1) WO2003039545A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1443927B1 (de) * 2001-11-07 2007-01-10 Millennium Pharmaceuticals, Inc. Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
BRPI0409263A (pt) * 2003-04-09 2006-03-28 Millennium Pharm Inc composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita
DE10326821A1 (de) * 2003-06-11 2005-01-05 Medical Enzymes Ag Pharmazeutische Kombinationspräparate zur Krebstherapie
KR20070014166A (ko) 2004-04-09 2007-01-31 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료에 유용한 베타-카르볼린
CN100443178C (zh) 2006-03-10 2008-12-17 中国石油天然气股份有限公司 一种乙烯低聚的催化剂组合物及其应用
CA2646316C (en) 2006-03-15 2016-05-24 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2009020877A2 (en) * 2007-08-03 2009-02-12 The Regents Of The University Of California Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof
WO2009054965A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Salts of n- (6-chloro-9h-pyrido [3,4-b] ind0l-8-yl) -4- [2- (2, 6-dimethyl-4-morpholinyl) -2-0x0e thyl] -6, 6-dimethyl-morpholinecarboxamide
US20090137579A1 (en) * 2007-10-23 2009-05-28 Millennium Pharmaceuticals, Inc. Mesylate salt of an IKK inhibitor
CN104059066A (zh) * 2008-06-11 2014-09-24 健泰科生物技术公司 二氮杂咔唑和使用方法
EP2161271A1 (de) * 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-Carbolin-Hemmer von NMP-ALK, RET und Bcr-Abl
WO2010099445A2 (en) * 2009-02-26 2010-09-02 Board Of Trustees Of Michigan State University Non-covalent inhibition of the 26s proteasome and uses thereof
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
FR2953837B1 (fr) * 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
EP3318563A1 (de) 2016-11-07 2018-05-09 Sanofi Substituierte pyrido[3,4-b]indole zur behandlung von knorpelerkrankungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2303627B (en) 1995-07-26 1997-07-09 Arab Pharmaceutical Mfg Co Ltd Anti-tumour platinum-harmine complex
WO1999012567A1 (en) * 1997-09-10 1999-03-18 Uab Research Foundation Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
JPH11180873A (ja) * 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
DE19807993A1 (de) 1998-02-26 1999-09-02 Bayer Ag Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
HUP0102782A3 (en) * 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001068648A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
AU3741801A (en) 2000-03-15 2001-09-24 Aventis Pharma Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
EP1443927B1 (de) * 2001-11-07 2007-01-10 Millennium Pharmaceuticals, Inc. Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas

Also Published As

Publication number Publication date
US20050049265A1 (en) 2005-03-03
HK1069311A1 (en) 2005-05-20
EP1443927B1 (de) 2007-01-10
AU2002352498A1 (en) 2003-05-19
JP2010031061A (ja) 2010-02-12
DE60217532T2 (de) 2007-10-31
JP2005529842A (ja) 2005-10-06
DE60217532D1 (de) 2007-02-22
EP1443927A2 (de) 2004-08-11
JP4599501B2 (ja) 2010-12-15
WO2003039545A2 (en) 2003-05-15
WO2003039545A3 (en) 2003-10-30
US9248124B2 (en) 2016-02-02

Similar Documents

Publication Publication Date Title
DE60217532D1 (de) Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
DE502004008604D1 (de) Pyrrolopyridin-substitutierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602004020793D1 (de) 5-phenyl-4-methyl-thiazol-2-yl-amin-derivate als inhibitoren von phosphatidylinositol-3-kinase-enzymen (pi3) zur behandlung entzündlicher erkrankungen der luftwege
DE60327438D1 (de) Amino-substituierte cyclohexan derivate zur behandlung bakterieller infektionen
CY2015003I2 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
ATE374610T1 (de) 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
ATE557021T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
ATE331512T1 (de) Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
AU2002338807A1 (en) Use of c-kit inhibitors for the treatment of myeloma
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60328494D1 (de) Verbessertes system zur behandlung der stressbedingten harninkontinenz
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
DE60325855D1 (de) Rifampicin zur Behandlung der Angiogenese
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
ATE528004T1 (de) Chinolon-antibiotika zur behandlung von periodontaler infektionen
ATE448228T1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
ATE430577T1 (de) Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition